Resource Summary Report

Generated by RRID on Aug 26, 2026

L-02

RRID:CVCL_6926
Type: Cell Line

Proper Citation

Ubigene Cat# YC-D004, RRID:CVCL_6926

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_6926

Proper Citation: Ubigene Cat# YC-D004, RRID:CVCL_6926

Description: Cell line L-02 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Human papillomavirus-related endocervical adenocarcinoma

Defining Citation: PMID:23498809, PMID:23505090, PMID:26116706, PMID:26143199, PMID:27027780

Comments: Population: African American., Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a normal fetal liver..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: L-02

Synonyms: L02, LO2, HL-7702, HL7702, Liver-02, Human Liver-7702

Cross References: BTO:BTO_0005965, ChEMBL-Cells:CHEMBL4295475, ChEMBL-Targets:CHEMBL4296457, GEO:GSM936770, KCB:KCB 200511YJ, PubChem_Cell_line:CVCL_6926, TOKU-E:3606, Ubigene:YC-D004, Wikidata:Q54900854

ID: CVCL_6926

Vendor: Ubigene

Catalog Number: YC-D004

Hierarchy: cvcl_0030

Record Creation Time: 20250130T072032+0000

Record Last Update: 20260816T001357+0000

Ratings and Alerts

No rating or validation information has been found for L-02.

Warning: Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a normal fetal liver.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00575.
Population: African American., Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a normal fetal liver..

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 923 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Dong Y, et al. (2026) KSRP-dependent immunogenic cell death induced by pyridazinone derivative IMB5036 drives antitumor immunity in neuroblastoma. FEBS letters.

Xu X, et al. (2026) Ultra-Radiostable Covalent Conformationally Interlocked Networks Enabling a Universal Radiometal-Labeling Platform for Cancer Radioembolization. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e76278.

Shao Z, et al. (2026) Src-mediated PHB2 phosphorylation disrupts mitochondrial cristae through cardiolipin dissociation in hepatocellular carcinoma. Redox biology, 91, 104073.

Wang W, et al. (2026) The rs713586 risk variant dysregulates ADCY3 rather than DNAJC27, leading to obesity through ZFP42-TET1-mediated DNA methylation. EBioMedicine, 123, 106112.

Li Z, et al. (2026) Bio-inspired fractal-structured gel-drugs enable enhancing deep tumor penetration for efficient chemotherapy of hepatocellular carcinoma. Journal of controlled release : official journal of the Controlled Release Society, 394, 114899.

Shi H, et al. (2026) CENPA as a Genome Stability-Associated Biomarker in Hepatocellular Carcinoma: Multiomics Analysis and Experimental Validation. Human mutation, 2026,

9292971.

Hou H, et al. (2026) Design, Synthesis, and Biological Evaluation of Novel Tetrandrine Derivatives Targeting AKT1 for Hepatocellular Carcinoma Therapy: Integration of Network Pharmacology, Molecular Dynamics Simulation, and Experimental Validation. ACS omega, 11(21), 30812.

Wang B, et al. (2026) An ultrasensitive chemiluminescent probe for cysteine detection in food and biological samples. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 363(Pt 2), 128383.

Xia Y, et al. (2025) Functional Modular Stacking Nanoprobes Based on Bimetallic Doped Carbon Dots for Multimodal Bioimaging and Photothermal Combined Tumor Therapy. Advanced healthcare materials, e04706.

Li Y, et al. (2025) LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma. Cell death discovery, 11(1), 269.

Wang X, et al. (2025) Berberine dissociates mitochondrial complex I by SIRT3-dependent deacetylation of NDUFS1 to improve hepatocellular glucose and lipid metabolism. Science China. Life sciences, 68(9), 2676.

Chang S, et al. (2025) Succinate supplementation alleviates liver cancer by inhibiting the FN1/SQLE axis-mediated cholesterol biosynthesis. iScience, 28(2), 111731.

Weiskirchen R, et al. (2025) Misidentified cell lines: failures of peer review, varying journal responses to misidentification inquiries, and strategies for safeguarding biomedical research. Research integrity and peer review, 10(1), 12.

Jiang J, et al. (2025) Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism. Cell metabolism, 37(5), 1119.

Zhou Y, et al. (2024) Prognostic, oncogenic roles, and pharmacogenomic features of AMD1 in hepatocellular carcinoma. Cancer cell international, 24(1), 398.

Mu M, et al. (2024) Targeting Ferroptosis-Elicited Inflammation Suppresses Hepatocellular Carcinoma Metastasis and Enhances Sorafenib Efficacy. Cancer research, 84(6), 841.

Bai Y, et al. (2024) Silibinin, a commonly used therapeutic agent for non-alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15/19. British journal of pharmacology, 181(19), 3663.

Shin GC, et al. (2024) Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis. British journal of pharmacology, 181(19), 3717.

Chen Z, et al. (2024) SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion. Oncoimmunology, 13(1), 2376264.

Guo Y, et al. (2024) Design, synthesis and biological evaluation of novel podophyllotoxin derivatives as tubulin-targeting anticancer agents. Pharmaceutical biology, 62(1), 233.